Skip to main content

Advertisement

SpringerLink
Log in

ASO Author Reflections: Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Amaria RN, Menzies AM, Burton EM, et al. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol. 2019;20(7):378–89.

    Article  Google Scholar 

  2. Amaria RN, Reddy SM, Tawbi HA, et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018;24(11):1649–54.

    Article  CAS  Google Scholar 

  3. Rozeman EA, Menzies AM, van Akkooi ACJ, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomized, controlled trial. Lancet Oncol. 2019;20(7):948–60.

    Article  CAS  Google Scholar 

  4. Daud AI, Loo K, Pauli ML, et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest. 2016;126(9):3447–52.

    Article  Google Scholar 

  5. Loo K, Tsai KK, Mahuron K, et al. Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy. JCI Insight. 2017;2(14): e93433.

    Article  Google Scholar 

  6. Levine LS, Mahuron KM, Tsai KK, et al. Tumor immune profiling based neoadjuvant immunotherapy for locally advanced melanoma. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08648-7.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, University of California, San Francisco, CA, USA

    Kelly M. Mahuron MD

  2. Department of Medicine, University of California, San Francisco, CA, USA

    Lauren S. Levine MD & Adil I. Daud MBBS

Authors
  1. Kelly M. Mahuron MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lauren S. Levine MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Adil I. Daud MBBS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adil I. Daud MBBS.

Ethics declarations

Disclosures

Adil Daud - Research Funding from Novartis, Roche/Genentech, Pfizer, BMS, Merck, Checkmate, Incyte and OncoSec. Stock in Trex bio.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mahuron, K.M., Levine, L.S. & Daud, A.I. ASO Author Reflections: Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma. Ann Surg Oncol 27, 4131–4132 (2020). https://doi.org/10.1245/s10434-020-08672-7

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-020-08672-7

Search

Navigation